Abstract:Pulmonary fibrosis (PF) is a type of interstitial pneumonia with complex etiology and high mortality, characterized by progressive scarring of the alveolar interstitium and myofibroblastic lesions. Recently, there has been growing appreciation of the importance of long non-coding RNAs (lncRNAs) in organ fibrosis. The aim of this study was to investigate the role of lncRNAs in lung fibrosis. We used a qRT-PCR assay to identify dysregulated lncRNAs in the lungs of mice with experimental, bleomycin (BLM)-induced pulmonary fibrosis, and a series of molecular assays to assess the role of the novel lncRNA NONMMUT060091, designated as pulmonary fibrosis inhibitor (PFI), which was significantly downregulated in lung fibrosis. Functionally, knockdown of endogenous PFI by smart silencer promoted proliferation, differentiation, and extracellular matrix (ECM) deposition in primary mouse lung fibroblasts (MLFs). In contrast, overexpression of PFI partially abrogated TGF-β1-induced fibrogenesis both in MLFs and in the human fetal lung fibroblast MRC-5 cells. Similarly, PFI overexpression attenuated BLM-induced pulmonary fibrosis compared with wild type (WT) mice. Mechanistically, using chromatin isolation by RNA purification-mass spectrometry (ChIRP-MS) and an RNA pull-down assay, PFI was found to directly bind Serine/arginine-rich splicing factor 1 (SRSF1), and to repress its expression and pro-fibrotic activity. Furthermore, silencing of SRSF1 inhibited TGF-β1-induced proliferation, differentiation, and ECM deposition in MRC-5 cells by limiting the formation of the EDA+Fn1 splicing isoform; whereas forced expression of SRSF1 by intratracheal injection of adeno-associated virus 5 (AAV5) ablated the anti-fibrotic effect of PFI in BLM-treated mice. Overall, these data reveal that PFI mitigated pulmonary fibrosis through negative regulation of the expression and activity of SRSF1 to decrease the formation of the EDA+Fn1 splicing isoform, and suggest that PFI and SRSF1 may serve as potential targets for the treatment of lung fibrosis.

Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity

Neuropilin-1 Identifies a New Subpopulation of TGF--Induced Foxp3<SUP>+</SUP> Regulatory T Cells With Potent Suppressive Function and Enhanced Stability During Inflammation

NRP1 downregulation correlates with enhanced ILC2 responses during IL‐33 challenge

Neuropilin-1 Identifies a New Subpopulation of TGF-β-Induced Foxp3+ Regulatory T Cells With Potent Suppressive Function and Enhanced Stability During Inflammation

Cis-acting Lnc-Cxcl2 Restrains Neutrophil-Mediated Lung Inflammation by Inhibiting Epithelial Cell CXCL2 Expression in Virus Infection

Neural Regulation of Interactions Between Group 2 Innate Lymphoid Cells and Pulmonary Immune Cells

The Origin and Role of Innate Lymphoid Cells in the Lung

Neuropilin-1, an immune checkpoint for controlling tumor-specific CD8 T-cell functions whose blockade improves anti-PD-1 immunotherapy

Ncf1 Governs Immune Niches in the Lung to Mediate Pulmonary Inflammation in Mice

The contribution of neuropilin-1 in the stability of CD4+ CD25+ regulatory T cells through the TGF-β1/Smads signaling pathway in the presence of lipopolysaccharides

NLRP6 negatively regulates type 2 immune responses in mice

PAC1 constrains type 2 inflammation through promotion of CGRP signaling in ILC2s

Neuropilin 1 Modulates TGF‑β1‑induced Epithelial‑mesenchymal Transition in Non‑small Cell Lung Cancer

Nr4a1 marks a distinctive ILC2 activation subset in the mouse inflammatory lung

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1

The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1

Neuropilin-1 high monocytes protect against neonatal inflammation

Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome

Specific Regulation of Prmt1 Expression by Pias1 and Rkip in Beas-2b Epithelia Cells and Hfl-1 Fibroblasts in Lung Inflammation

How Neuropilin-2 and Macrophages Contribute to Cardiothoracic Disease

Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF